Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd maintains a strong liquidity position, with a current ratio of 11.17, indicating that the company has significantly more current assets than current liabilities. The company's liquidity is assessed as medium, and its capital structure is largely equity-driven, with total equity of 893,865,510.0 and total liabilities of 72,287,620.0. The company's debt-to-equity ratio is 0.0, suggesting no long-term debt obligations.

In terms of profitability, the company reported a net income of 10,408,870.0 and an operating income of 12,262,480.0. The return on equity (ROE) is 1.16%, and the return on assets (ROA) is 1.08%. These figures suggest that the company is generating modest returns relative to its equity and asset base, which may be below the industry median for pharmaceutical firms.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed breakdown of geographic exposure or segment performance provided in the available data. However, the company's operations are likely centered in China, given its listing on the Shenzhen Stock Exchange.

The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The capital expenditure of -65,289,560.0 suggests a significant outflow in the period, potentially related to investments in new facilities or equipment. The operating cash flow of 32,576,620.0 indicates that the company is generating positive cash from operations, which supports its liquidity position.

The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the risk assessment notes that net cash is negative after subtracting total debt, which could indicate potential liquidity constraints if not managed properly. The company's capital structure is currently stable, with no long-term debt obligations, but this could change if the company decides to take on debt for expansion or other strategic initiatives.

There are no recent events or filings provided in the available data that would indicate significant changes in the company's operations or financial position. The company's financial statements are the primary source of information for the current analysis.

The company maintains a zero long-term debt balance, resulting in a debt-to-equity ratio significantly better than the cohort median.

Cash conversion efficiency is rated best-in-class at 3.13, substantially outperforming the cohort median of 0.95.

Free cash flow turned positive to 49.2 million in FY-4, reversing the negative trend from previous fiscal years.

Dilution and credit risks are assessed as low, providing a stable capital structure for long-term investors.

Return on equity of 1.16% falls below the cohort median of 2.91%, indicating inefficient capital utilization.

Capital expenditure intensity is in the bottom quartile, suggesting potential underinvestment in future growth drivers.

Liquidity risk is rated as medium, posing potential challenges for short-term operational funding requirements.

Return on assets of 1.08% remains low, reflecting limited profitability relative to the total asset base employed.